Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) has received a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $170.67.
Several equities research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday. William Blair initiated coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They issued an “outperform” rating on the stock. Leerink Partners initiated coverage on shares of Tenax Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Guggenheim initiated coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock.
View Our Latest Analysis on TENX
Tenax Therapeutics Stock Up 10.6 %
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($1.99) by $0.16. On average, equities research analysts forecast that Tenax Therapeutics will post -6.75 EPS for the current fiscal year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Tenax Therapeutics
- How to Find Undervalued Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Which Wall Street Analysts are the Most Accurate?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.